文献速递慢性静脉疾病

FOVELASS:腔内激光消融与聚多卡醇泡沫硬化剂治疗小隐静脉功能不全的随机试验

FOVELASS: A Randomised Trial of Endovenous Laser Ablation Versus Polidocanol Foam for Small Saphenous Vein Incompetence.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2022-12-05

多中心随机对照试验纳入161例孤立性小隐静脉功能不全患者,随机分至超声引导泡沫硬化疗法组(n=82)或腔内激光消融组(n=79),随访3年。激光组3年无返流率86%显著优于泡沫组56%(OR 5.36,95%CI 2.31-12.44),但两组临床评分与生活质量改善相似。

要点

  • 激光组3年完全无返流率86%,显著高于泡沫组56%(OR 5.36,95%CI 2.31-12.44)。
  • 两组3年可见静脉曲张率、修订静脉临床严重程度评分及生活质量无差异。
  • 激光组发生2例深静脉血栓和1例腔内热诱导血栓,泡沫组发生7例深静脉血栓。

核心结论

  • 小隐静脉治疗后3年,腔内激光消融的技术成功率优于超声引导泡沫硬化疗法,与大腿静脉相关研究结果一致,但两组临床结局改善相似。

研究设计与样本

  • 多中心随机对照试验(ClinicalTrials.gov标识NCT05468450),纳入年龄≥18岁、接受孤立性小隐静脉治疗(返流>0.5秒)的患者,随机分至超声引导泡沫硬化疗法组或腔内激光消融组。

主要发现

  • 筛查1522例患者,161例随机分组:泡沫组82例,激光组79例;泡沫组仅3%接受了允许的第二次干道治疗,86%完成3年研究。
  • 3年完全无返流率激光组86% vs 泡沫组56%(OR 5.36,95%CI 2.31-12.44;风险比1.59,95%CI 1.26-2.01)。
  • 激光组发生2例深静脉血栓(1例股腘静脉、1例腓肠肌静脉)和1例腔内热诱导血栓;泡沫组发生7例深静脉血栓,包括2例部分腘静脉血栓和5例腓肠肌静脉血栓(其中4例无症状,于第8天筛查时偶然发现)。
  • 3年时两组可见静脉曲张率(p=0.87)、修订静脉临床严重程度评分(p=0.28)和生活质量(p=0.59)无差异。
  • 患者满意度评分两组均高(中位数:激光组97/100,泡沫组93/100;p=0.080),两组症状均显著改善(p<0.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the outcomes of ultrasound guided foam sclerotherapy (UGFS) and endovenous laser ablation (EVLA) to treat isolated small saphenous vein (SSV) incompetence in a multicentre randomised controlled study (RCT; ClinicalTrials.gov identifier: NCT05468450). METHODS: Patients aged ≥ 18 years undergoing isolated SSV treatment (reflux > 0.5 seconds) were randomised to UGFS or EVLA. Patients treated with UGFS were allowed one additional truncal treatment at six weeks. Tributary treatments (phlebectomy or sclerotherapy) were permitted after six months. Participants were assessed at eight days, six months, and one, two, and three years. The primary endpoint was the absence of SSV reflux (> 0.5 seconds). Secondary outcomes included clinical scores and quality of life (QoL) scores. All analyses were done by intention to treat. RESULTS: Of 1 522 screened patients, 161 were randomised to UGFS (n = 82) and EVLA (n = 79). Only 3% of patients who received UGFS had the second (allowed) treatment and 86% of patients completed the three year study. Forty-one and 19 tributary treatments (by sclerotherapy) were performed in 27 UGFS patients (33%) and 15 EVLA patients (19%), respectively. The complete absence of reflux at three years was significantly better after EVLA (86%) than after UGFS (56%) (odds ratio [OR] 5.36, 95% confidence interval [CI] 2.31 - 12.44; risk ratio 1.59, 95% CI 1.26 - 2.01). Two deep vein thromboses (DVTs; one femoropopliteal and one gastrocnemius) and one endovenous heat induced thrombosis occurred in the EVLA group. Seven DVTs were seen in the UGFS group, including two partial popliteal DVTs and five gastrocnemius vein thromboses (four asymptomatic and incidental on day 8 screening). At three years, there was no difference between groups for the following: rate of visible varices (p = .87), revised Venous Clinical Severity Score (p = .28), and QoL (p = .59). Patient satisfaction scores were high in both groups (median score: EVLA 97/100 and UGFS 93/100; p = .080). Symptoms were significantly improved in both groups. (p < .001) CONCLUSION: Technical success was better for EVLA than for UGFS three years after SSV treatment. This agrees with studies that have reported on these treatments in the great saphenous vein. However, improvements in clinical outcome were similar for both groups.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hamel-Desnos C, Nyamekye I, Chauzat B, et al. FOVELASS: A Randomised Trial of Endovenous Laser Ablation Versus Polidocanol Foam for Small Saphenous Vein Incompetence. Eur J Vasc Endovasc Surg. 2022. PMID: 36470312. doi:10.1016/j.ejvs.2022.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。